Immunocore (IMCR) grants CFO RSUs and stock options with multi-year vesting

Rhea-AI Filing Summary

Coy Travis Alan reported acquisition or exercise transactions in this Form 4 filing.

Immunocore Holdings plc reported that Chief Financial Officer Travis Alan Coy received new equity awards. On February 17, 2026, he was granted 33,353 Restricted Share Units, each representing a contingent right to receive one Ordinary Share, which vest in four equal annual installments starting February 17, 2027, subject to continuous service.

He was also granted an option over 95,637 shares, with 25% vesting on February 17, 2027 and 6.25% vesting in quarterly installments thereafter, also subject to continuous service. Ordinary Shares may be represented by American Depositary Shares, with each ADS equal to one Ordinary Share.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Coy Travis Alan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	33,353	$0.00	--
Grant/Award	Employee Share Option (Right to Buy)	95,637	$0.00	--

Holdings After Transaction: Restricted Share Units — 33,353 shares (Direct); Employee Share Option (Right to Buy) — 95,637 shares (Direct)

Footnotes (1)

1. Each restricted share unit ("RSU") represents a contingent right to receive one Ordinary Share. The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date. Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share. 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coy Travis Alan

(Last) (First) (Middle)

C/O IMMUNOCORE HOLDINGS PLC

92 PARK DRIVE, MILTON PARK

(Street)

ABINGDON, OXFORDSHIRE X0 OX14 4RY

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunocore Holdings plc [ IMCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	02/17/2026		A		33,353		(2)	(2)	Ordinary Shares(3)	33,353	$0	33,353	D
Employee Share Option (Right to Buy)	$32.38	02/17/2026		A		95,637		(4)	02/16/2036	Ordinary Shares(3)	95,637	$0	95,637	D

Explanation of Responses:

1. Each restricted share unit ("RSU") represents a contingent right to receive one Ordinary Share.

2. The RSUs vest in four equal annual installments beginning February 17, 2027, subject to the Reporting Person's continuous service through each such vesting date.

3. Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share represents one Ordinary Share.

4. 25% of the shares subject to the option award shall vest on February 17, 2027, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.

	/s/ Lily Hepworth, Attorney-in-Fact	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Immunocore (IMCR) grant to its CFO?

Immunocore granted CFO Travis Alan Coy 33,353 Restricted Share Units and an option over 95,637 shares. These awards provide future rights to Ordinary Shares, subject to multi-year vesting and his continued service with the company.

How do the new RSUs for Immunocore (IMCR) CFO vest?

The 33,353 Restricted Share Units vest in four equal annual installments starting February 17, 2027. Each vested RSU delivers one Ordinary Share, assuming the CFO remains continuously employed through each vesting date specified in the award terms.

What is the vesting schedule for the Immunocore (IMCR) CFO stock options?

The option over 95,637 shares vests with 25% on February 17, 2027, then 6.25% quarterly thereafter. Vesting depends on the CFO’s continuous service through each vesting date, aligning long-term incentives with ongoing employment.

What does each Immunocore (IMCR) RSU granted to the CFO represent?

Each Restricted Share Unit represents a contingent right to receive one Ordinary Share. Delivery occurs as the RSUs vest over time, subject to the CFO meeting the continuous service conditions outlined in the award agreement.

How are Immunocore (IMCR) Ordinary Shares related to American Depositary Shares?

Immunocore’s Ordinary Shares may be represented by American Depositary Shares. Each American Depositary Share corresponds to one Ordinary Share, providing an equivalent economic interest for holders of ADSs and Ordinary Shares.

Were the Immunocore (IMCR) CFO equity awards open-market purchases or grants?

The transactions were equity grants, not open-market purchases. They are classified as awards acquired at a stated price of $0.00 per share, reflecting standard incentive compensation rather than cash-funded share purchases.